BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018;68:895-903. [PMID: 29221887 DOI: 10.1016/j.jhep.2017.11.032] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Jindal A. Letter to the editor: Oral antivirals in treatment-naïve chronic hepatitis C infection. Hepatology 2022. [PMID: 34984728 DOI: 10.1002/hep.32311] [Reference Citation Analysis]
2 Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85. [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
3 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Velosa J, Macedo G. Elimination of Hepatitis C in Portugal: An Urban Legend? GE Port J Gastroenterol 2020;27:166-71. [PMID: 32509922 DOI: 10.1159/000505582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nguyen T, Valantin MA, Delaugerre C, Amiel C, Netzer E, L'Yavanc T, Ohayon M, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. J Glob Antimicrob Resist 2021;24:311-5. [PMID: 33540082 DOI: 10.1016/j.jgar.2021.01.012] [Reference Citation Analysis]
6 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liu Z, Mao X, Yu K, Suo C, Jin L, Zhang T, Chen X. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents. J Viral Hepat 2020;27:585-92. [PMID: 32049405 DOI: 10.1111/jvh.13270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Smith DA, Bradshaw D, Mbisa JL, Manso CF, Bibby DF, Singer JB, Thomson EC, da Silva Filipe A, Aranday-Cortes E, Ansari MA, Brown A, Hudson E, Benselin J, Healy B, Troke P, McLauchlan J, Barnes E, Irving WL. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. J Viral Hepat 2021;28:1256-64. [PMID: 34003556 DOI: 10.1111/jvh.13549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther 2018;47:1690-8. [PMID: 29665069 DOI: 10.1111/apt.14647] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
10 Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
11 Pérez-Hernández JL, Arce-Salinas CA, Lehmann-Mendoza R, Torre-Delgadillo A, Castro-Narro GE, Cerda-Reyes E, Ramos-Gómez MV, Juárez-Chavez L, Dehesa-Violante M, Muñoz-Espinoza LE, Cisneros-Garza LE, Aiza-Haddad I, Velarde-Ruiz-Velasco JA, Contreras-Omaña R, García-Casarreal N, Carmona-Castañeda A, Higuera-De la Tijera F. Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00111-0. [PMID: 34774460 DOI: 10.1016/j.rgmxen.2021.10.006] [Reference Citation Analysis]
12 Pronier C, Fontaine H, Dorival C, Carrat F, Pol S, Thibault V; AFEF/ANRS Hepather study group. Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. J Viral Hepat 2019;26:1276-83. [PMID: 31273896 DOI: 10.1111/jvh.13171] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Adeboyejo K, Grosche VR, José DP, Ferreira GM, Shimizu JF, King BJ, Tarr AW, Soares MMCN, Ball JK, Mcclure CP, Jardim ACG. Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000326] [Reference Citation Analysis]
14 Moutinho-Ribeiro P, Costa-Moreira P, Adem B, Batista I, Almeida M, Barroca H, Lopes J, Carneiro F, Melo SA, Macedo G. Exosomal glypican-1 for risk stratification of pancreatic cystic lesions: A case of pathological progression in the absence of any suspicious imaging finding. Pancreatology 2020;20:571-5. [PMID: 32024605 DOI: 10.1016/j.pan.2020.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, Chevaliez S, Pawlotsky JM. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology 2019;69:513-23. [PMID: 30125371 DOI: 10.1002/hep.30225] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
16 AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018;67:1477-92. [PMID: 30215672 DOI: 10.1093/cid/ciy585] [Cited by in Crossref: 277] [Cited by in F6Publishing: 243] [Article Influence: 92.3] [Reference Citation Analysis]
17 Liu CH, Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. J Formos Med Assoc 2020;119:1871-5. [PMID: 32553687 DOI: 10.1016/j.jfma.2020.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wuerth K, Magel T, Conway B. Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. Future Virology 2019;14:715-27. [DOI: 10.2217/fvl-2019-0104] [Reference Citation Analysis]
19 Huang SC, Kao JH. Strategies for hepatitis C virus treatment failure. J Formos Med Assoc 2021:S0929-6646(21)00426-5. [PMID: 34538553 DOI: 10.1016/j.jfma.2021.09.004] [Reference Citation Analysis]
20 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 de Torres Santos AP, Martins Silva VC, Mendes-Corrêa MC, Lemos MF, de Mello Malta F, Santana RAF, Dastoli GTF, de Castro VFD, Pinho JRR, Moreira RC. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. Infect Drug Resist 2021;14:723-30. [PMID: 33658809 DOI: 10.2147/IDR.S247071] [Reference Citation Analysis]
22 Hayes CN, Imamura M, Chayama K. Management of HCV patients in cases of direct-acting antiviral failure. Expert Rev Gastroenterol Hepatol. 2019;13:839-848. [PMID: 31392907 DOI: 10.1080/17474124.2019.1651642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70:1019-1023. [PMID: 30857780 DOI: 10.1016/j.jhep.2019.01.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
24 Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver Int 2020. [PMID: 32640072 DOI: 10.1111/liv.14591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
26 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
27 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Reference Citation Analysis]
28 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology 2021;74:1472-82. [DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
29 Sulkowski M, Wyles D. Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions. Clin Infect Dis 2021;73:e3296-9. [PMID: 32887999 DOI: 10.1093/cid/ciaa1329] [Reference Citation Analysis]
30 Han B, Martin R, Xu S, Parvangada A, Svarovskaia ES, Mo H, Dvory-Sobol H. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects. Antiviral Res 2019;170:104574. [PMID: 31394118 DOI: 10.1016/j.antiviral.2019.104574] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Lu YM, Yang WL, Chang CY, Ling SM, Liu CY, Wei J, Yang HS. Clinical Experience of Patients With Hepatitis C Treated With Direct-Acting Antivirals After Heart Transplantation. Transplant Proc 2021;53:665-72. [PMID: 33341262 DOI: 10.1016/j.transproceed.2020.10.035] [Reference Citation Analysis]
32 Malandris K, Kalopitas G, Theocharidou E, Germanidis G. The Role of RASs /RVs in the Current Management of HCV. Viruses 2021;13:2096. [PMID: 34696525 DOI: 10.3390/v13102096] [Reference Citation Analysis]
33 Gupta E, Agarwal R, Rastogi A, Rani N, Jindal A. Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV-HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy. Infect Drug Resist 2021;14:1381-7. [PMID: 33880042 DOI: 10.2147/IDR.S301032] [Reference Citation Analysis]
34 Nakamura H, Akagi Y, Terui T, Fujioka S, Komoda Y, Kinoshita W, Maeda K, Ukaji Y, Inaba T. Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity. Bioorg Med Chem Lett 2020;30:126932. [PMID: 31952964 DOI: 10.1016/j.bmcl.2019.126932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018; 10(9): 543-548 [PMID: 30310532 DOI: 10.4254/wjh.v10.i9.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
36 Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators., Spanish GEHEP-004 Collaborators., Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol 2021;74:801-10. [PMID: 33220331 DOI: 10.1016/j.jhep.2020.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
37 Wang GP, Schnell GL, Kort JJ, Sidhu GS, Schuster L, Tripathi RL, Larsen L, Michael LC, Bergquist K, Magee A, Patel CB, Whitlock JA, Tamashiro R, Peter JA, Fried MW, Nelson DR. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. J Hepatol 2021:S0168-8278(21)00339-1. [PMID: 34023351 DOI: 10.1016/j.jhep.2021.04.057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol 2018;69:603-7. [PMID: 29886154 DOI: 10.1016/j.jhep.2018.05.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
39 Douglas MW, Tay ESE, Wang DS, Ong ATL, Wilson C, Phu A, Kok J, Dwyer DE, Bull RA, Lloyd AR, Applegate TL, Dore GJ, Howe AY, Harrigan R, George J. Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatol Commun 2020;4:904-15. [PMID: 32490325 DOI: 10.1002/hep4.1496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents. Antimicrob Agents Chemother 2019;63:e02205-18. [PMID: 30718256 DOI: 10.1128/AAC.02205-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
41 Fedorchenko SV, Martynovych T, Klimenko Z, Yanchenko V, Solianyk I. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin. J Viral Hepat 2020;27:548-51. [PMID: 31894886 DOI: 10.1111/jvh.13254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, Ouzan D, Papatheodoridis G, Ramji A, Borgia SM, Wedemeyer H, Losappio R, Pérez-Hernandez F, Wick N, Brown RS Jr, Lampertico P, Doucette K, Ntalla I, Ramroth H, Mertens M, Vanstraelen K, Turnes J. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int 2020;40:1841-52. [PMID: 32449966 DOI: 10.1111/liv.14537] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
43 Wei L, Omata M, Lim Y, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han K, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research 2018;158:178-84. [DOI: 10.1016/j.antiviral.2018.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
44 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
45 Sayan M, Yıldırım FS, Akhan S, Yıldırım AA, Şirin G, Cabalak M, Demir M, Can S, Ersöz G, Altıntaş E, Ensaroğlu F, Akbulut A, Şener A, Deveci A. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Int J Infect Dis 2020;95:84-9. [PMID: 32302766 DOI: 10.1016/j.ijid.2020.03.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Papaluca T, O'Keefe J, Bowden S, Doyle JS, Stoove M, Hellard M, Thompson AJ. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol 2019;120:84-7. [PMID: 31606586 DOI: 10.1016/j.jcv.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Huang CF, Yu ML. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol 2020;26:251-60. [PMID: 32188235 DOI: 10.3350/cmh.2020.0018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
48 Liu X, Hu P. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. J Clin Transl Hepatol 2021;9:125-32. [PMID: 33604263 DOI: 10.14218/JCTH.2020.00078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tao YC, Deng R, Wang ML, Lv DD, Yuan M, Wang YH, Chen EQ, Tang H. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. Virol J 2018;15:150. [PMID: 30285800 DOI: 10.1186/s12985-018-1066-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
50 Nakamura H, Fujioka S, Terui T, Okuda S, Kondo K, Tamatani Y, Akagi Y, Komoda Y, Kinoshita W, Ito S, Maeda K, Ukaji Y, Inaba T. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. Bioorg Med Chem Lett 2020;30:127361. [PMID: 32738974 DOI: 10.1016/j.bmcl.2020.127361] [Reference Citation Analysis]
51 Fedorchenko SV, Martynovych T, Klimenko Z, Solianyk I. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. J Med Virol 2021;93:4975-81. [PMID: 33704798 DOI: 10.1002/jmv.26935] [Reference Citation Analysis]
52 Pham LV, Ramirez S, Gottwein JM, Fahnøe U, Li YP, Pedersen J, Bukh J. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology 2018;154:2194-2208.e12. [PMID: 29454794 DOI: 10.1053/j.gastro.2018.02.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
53 Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. J Infect 2019;79:503-12. [PMID: 31629015 DOI: 10.1016/j.jinf.2019.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
54 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
55 Dvory-Sobol H, Han B, Lu J, Yu M, Beran RK, Cheng G, Martin R, Svarovskaia E, Mo H. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. J Viral Hepat 2019;26:991-1001. [PMID: 31009123 DOI: 10.1111/jvh.13116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Wang X, Wei L. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol 2021;9:419-27. [PMID: 34221928 DOI: 10.14218/JCTH.2020.00097] [Reference Citation Analysis]
57 Ohya K, Imamura M, Teraoka Y, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Mori N, Takaki S, Tsuji K, Aisaka Y, Ishitobi T, Katamura Y, Kodama H, Nabeshima Y, Masaki K, Honda Y, Moriya T, Kohno H, Kohno H, Chayama K. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res 2020;50:1234-43. [PMID: 32914512 DOI: 10.1111/hepr.13555] [Reference Citation Analysis]